Actithera: Radiopharma Funding Gathers Huge Momentum
The biotech company Actithera, with locations in Cambridge, USA, and Oslo, Norway, has successfully closed a major Series A round, raising US $75.5 million. Its isotope-agnostic platform — designed with a specific focus on the interaction between linker and target molecule — has attracted strong interest from a wide range of investors. However, the path to this achievement was not as straightforward as anticipated, CEO Andreas Goutopoulos told European Biotech News.